Research Analysts’ Recent Ratings Updates for Apellis Pharmaceuticals (APLS)

Several brokerages have updated their recommendations and price targets on shares of Apellis Pharmaceuticals (NASDAQ: APLS) in the last few weeks:

• 12/29/2025 – Apellis Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Apellis Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/19/2025 – Apellis Pharmaceuticals had its price target lowered by analysts at Stifel Nicolaus from $55.00 to $48.00. They now have a “buy” rating on the stock.
• 12/15/2025 – Apellis Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Apellis Pharmaceuticals had its “outperform” rating reaffirmed by analysts at William Blair.
• 12/8/2025 – Apellis Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Apellis Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Apellis Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Apellis Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Apellis Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – Apellis Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/6/2025 – Apellis Pharmaceuticals is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.

Insider Activity at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 31,092 shares of the firm’s stock in a transaction dated Friday, October 10th. The stock was sold at an average price of $23.72, for a total value of $737,502.24. Following the transaction, the director owned 3,837 shares in the company, valued at $91,013.64. This trade represents a 89.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Timothy Eugene Sullivan sold 10,000 shares of Apellis Pharmaceuticals stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $28.03, for a total value of $280,300.00. Following the completion of the sale, the chief financial officer owned 110,936 shares of the company’s stock, valued at approximately $3,109,536.08. The trade was a 8.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 56,092 shares of company stock valued at $1,366,652 over the last quarter. Corporate insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.